HillMed has been awarded a FastTrack Small Business Innovation Research (SBIR) grant from the National Institutes of Health (NIH) to develop its innovative HillMed EMG System for use with pelvic floor disorders. The cutting-edge technology aims to revolutionize the precision and personalization of botulinum toxin injections for Chronic Pelvic Pain (CPP) and closely related conditions.
HillMed’s device utilizes electromyography (EMG) to create detailed maps of muscle and nerve activity, including that happening within the pelvic floor. This personalized mapping allows for more accurate injections, potentially improving treatment outcomes and minimizing patient suffering.
The FastTrack SBIR grant combines Phase I and Phase II funding, providing HillMed with resources to accelerate development and commercialization efforts through September 2027. This support underscores the NIH’s commitment to fostering innovative solutions that address unmet medical needs.
HillMed’s achievement highlights the vital role of small businesses in driving medical innovation. By securing this grant, the company is poised to make significant strides in improving the quality of care for individuals affected by CPP and other debilitating pelvic floor disorders.
Stay tuned for updates on more effective and personalized EMG treatment options for pelvic health management.
